Status and phase
Conditions
Treatments
About
This is a phase I study, which tests the safety of different doses of lenvatinib in combination with cetuximab, to see which dose is the safest in people. This study will help find out if lenvatinib and cetuximab is a safe and useful combination for treating patients with HNSCC and cSCC.
Enrollment
Sex
Volunteers
Inclusion criteria
Exclusion criteria
Prior grade 3 hypersensitivity to cetuximab requiring discontinuation
Prior lenvatinib
Major surgery within 2 weeks of first dose of lenvatinib
Metastatic brain or leptomeningeal tumors (treated metastatic brain or leptomeningeal tumors are allowed).
Anticancer treatment (e.g., radiation therapy, chemotherapy) within 21 days of first dose
°An exception is cetuximab treatment, which can be received within 21 days of the first treatment on study
No prior palliative radiation to a target lesion is allowed, unless there is clear biopsy proven progression following radiation. Note, prior radiations to a non-target lesion is allowed. Please see section 9.3.Subjects having a spot Urine Protein:Creatinine ratio of >1 will undergo 24-hour collection for quantitative assessment of proteinuria. If urine protein > 1 gram/24 hours, the subject will be ineligible
Significant cardiovascular impairment within 6 months as defined as (1) congestive heart failure greater than New York Heart Association Class II, (2) unstable angina, (3) myocardial infarction; (4) stroke, (5) symptomatic cardiac arrhythmia
On electrocardiogram, QTc interval > 500 msec
Active infection requiring systemic therapy
Clinically significant hemoptysis or tumor bleeding within 2 weeks prior to first dose of lenvatinib
Other active malignancy except for basal cell or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or bladder
Women who are breast feeding or pregnant ° Men or women of reproductive potential who are not willing to employ effective birth control from screening to 30 days after the last dose of study drugs; the definition of adequate contraception will be based on the judgment of the principal investigator or a designated associate.
For a female patient to be considered as not of child bearing potential, she should fulfill one of the following:
° Post-menopausal women, defined as either women aged more than 50 years and amenorrhoeic for at least 12 months following cessation of all exogenous hormonal treatments, or, women under 50 years old who have been amenorrhoeic for at least 12 months following the cessation of exogenous hormonal treatments, and have serum follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels in the postmenopausal range for the institution.
Or
° Have documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy (but not tubal ligation)
Primary purpose
Allocation
Interventional model
Masking
24 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal